Safety outcomes:
Safety analyses included assessment of adverse events and central laboratory testing; serum potassium and creatinine levels. Adverse events that occurred during the treatment period were defined as those that started or worsened during finerenone or placebo intake or up to 3 days after any temporary or permanent interruption.